Could CAR T-Cells beat tough scleroderma? new trial aims to find out
NCT ID NCT07493395
First seen Apr 07, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This early trial tests a one-time CAR T-cell treatment for 6 adults with severe scleroderma that hasn't improved with standard drugs. The goal is to see if it can reduce skin thickening and other symptoms, and to check for side effects. Participants will get the cells by IV after a short chemotherapy, then be followed for 2 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLERODERMA, SYSTEMIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
APHP Necker
Paris, France
Contact
Contact Email: •••••@•••••
-
CHRU Lille
Lille, France
Contact Email: •••••@•••••
Contact
-
Chu Rouen
Rouen, France
Contact Email: •••••@•••••
-
Montpellier University Hospital
Montpellier, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.